Save up to 83% on Bosulif from Europe and over 95% with generic Bosulif from Insulinhub.com
Click here for information on Mylan generics (Immediate availability)
For Brand Bosulif, Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.
According to the European Medicines Agency, brand name Bosulif originating from Europe is manufactured at the following site(s):Pfizer Manufacturing Deutschland GmbH BetriebsstÓ“tte Freiburg Mooswaldallee 1 79090 Freiburg Germany
Information about Bosulif (Bosutinib)
Bosulif (Bosutinib) is a prescription medication used primarily for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults who are resistant or intolerant to prior therapies. It works by inhibiting certain proteins (tyrosine kinases) involved in the growth and spread of cancer cells.
Bosutinib the active ingredient in Bosulif, which selectively inhibits the BCR-ABL tyrosine kinase and other related kinases involved in the pathogenesis of CML and Ph+ ALL.
Product Highlights
- Used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults who are resistant to or intolerant of other treatments?
- Bosutinib is a tyrosine kinase inhibitor that targets and inhibits BCR-ABL and other related kinases, which are involved in the pathogenesis of these cancers.
- Demonstrated efficacy in clinical trials for treating resistant or intolerant cases of CML and Ph+ ALL.
Key Ingredient
Key Benefits
- Bosutinib specifically targets and inhibits BCR-ABL tyrosine kinase, which is crucial for the survival and proliferation of cancer cells in CML and Ph+ ALL.
- Provides an option for patients who have not responded to or cannot tolerate other treatments.
- Convenient as it is taken in tablet form, making it easier to adhere to the treatment regimen compared to intravenous options.
Direction for Use
- Typically, the recommended starting dose is 400 mg once daily. Dosage adjustments may be required based on side effects or disease response.
- Take Bosulif with food to help reduce gastrointestinal side effects. Swallow tablets whole with a full glass of water. Do not crush or chew tablets.
Safety Concern
- Common side effects may include diarrhea, nausea, vomiting, abdominal pain, fatigue, and headache.
- Can cause serious side effects like liver problems, blood cell count abnormalities (e.g., low white blood cells, anemia), or severe gastrointestinal issues.
- Regular blood tests are needed to monitor liver function and blood cell counts.
Avoid Bosulif (Bosutinib) If
- If you have a known hypersensitivity or allergy to bosutinib or any of the excipients in the formulation.
- Those with severe liver impairment should avoid using this medication as it can exacerbate liver issues.
- Avoid if you are taking medications that have significant interactions with bosutinib, such as certain strong CYP3A4 inducers or inhibitors.
